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Breast cancer is a leading cause of death in women around the world. Most breast
cancer-related deaths are a result of complications from the metastatic spread. Several
recent studies reported that high-risk human papillomaviruses (HPVs) and Epstein–Barr
virus (EBV) are co-presented in different types of human carcinomas including breast;
however, the cooperative effects between high-risk HPVs and EBV oncoproteins in
human breast cancer have not been investigated yet. Thus, we herein explored
the cooperation outcome between E6/E7 and latent membrane protein 1 (LMP1)
oncoproteins of high-risk HPV type 16 and EBV, respectively, in two human breast
cancer cell lines, MCF7 and MDA-MB-231. Our data revealed that the cooperation of
E6/E7 and LMP1 oncoproteins stimulates cell proliferation and deregulates cell cycle
progression of human breast cancer and normal mammary cells; in parallel, we noted
that E6/E7/LMP1 incite colony formation of both breast cancer cell lines but not normal
cells. More significantly, our results point out that the co-expression of E6/E7 and LMP1
oncoproteins enhances cell motility and invasion of MCF7 and MDA-MB-231 cell lines;
this is accompanied by deregulation of epithelial–mesenchymal transition biomarkers
including E-cadherin, β-catenin, fascin, and vimentin. The molecular pathway analysis of
HPV and EBV oncoproteins cooperation shows that it can enhance the phosphorylation
of extracellular signal-regulated kinases (Erk1/Erk2) in addition to β-catenin, which could
be behind the effect of this cooperation in our cell models. The study clearly suggests
that high-risk HPV and EBV coinfection can play an important role in breast cancer
progression via Erk1/Erk2 and β-catenin signaling pathways.
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INTRODUCTION
Breast cancer, the most commonly diagnosed cancer in women,
represents ∼25% of all cancer cases (1). While breast cancer is
the leading cause of mortality in developing countries (∼14%),
in developed countries, it is the second cause of cancer-related
mortality (∼15%) (1). Most breast cancer-related deaths result
from complications due to metastasis to vital organs including
the brain, bone, liver, and lung (2, 3). Breast cancer is a
complex and heterogeneous disease at the molecular level, with
different gene expression patterns leading to differences in
clinical behaviors and outcomes (4). On the one hand, based
on gene expression profiling of human breast tumors, they
are classified into four subtypes (luminal A, luminal B, human
epidermal growth factor receptor-2 (HER2)-positive, and triple-
negative) (5). On the other hand, it has been indicated that
gene alteration, lifestyle, and environmental factors play a vital
role in breast cancer etiology (6, 7). Additionally, it has been
recently pointed out that oncoviruses, such as high-risk human
papillomaviruses (HPVs) and Epstein–Barr virus (EBV), can be
involved in the onset and progression of breast cancer (8–15).
Globally, it has been shown that high-risk HPVs are present
in 2–86% of human breast cancer cases (10, 11, 13, 16–18), while
EBV is present in 30–50% of the cases (11, 19–22). However,
a few studies have failed to detect the presence of HPV or
EBV in breast cancer (23–26). The distribution of HPV in
breast cancer varies geographically; different countries including
Mexico, China, United Kingdom, Iran, India, Syria, and Qatar
reported a prevalence of 40–65% (10, 27–32), while others, such
as Japan and Jordan, reported a lower prevalence of around 21%
(33, 34). Similarly, a varying frequency of EBV infection has been
reported; in Jordan, Pakistan, Portugal, and Eritrea, EBV was
present in 24–28% (34), while a higher frequency was reported
in Qatar (49%), Syria (52%), and Sudan (53%), respectively (12,
35, 36). Co-presence of HPV and EBV has been reported in breast
cancer; coinfection in such cases is significantly higher in cancer
when compared to normal breast tissues (11). However, a study
in Australia showed co-presence of HPV and EBV in ∼76% of
breast cancers (11); in Qatar and Syria, coinfection was reported
in 47 and 32% of the cases, respectively (14, 32). In Pakistan, a
low frequency of 9% was revealed (37). On the other hand, a
study in Jordan identified multiple viral infections in 6% of breast
cancer cases (34). Moreover, an investigation by Glenn et al. (11)
demonstrated the co-presence of HPV and EBV in breast cancer
correlated with diagnosis at a younger age and a more aggressive
grade of breast cancer.
Nevertheless, it has been established by an earlier study
that E6/E7 oncoproteins of high-risk HPV type 16, the most
Abbreviations: DMEM, Dulbecco’s modified Eagle’s medium; DMSO, dimethyl
sulfoxide; EBV, Epstein–Barr virus; ERK, extracellular signal-regulated kinases;
FBS, fetal bovine serum; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
HER2, human epidermal growth factor receptor-2; HNME, human normal
mammary epithelial; HPV, human papillomavirus; LMP, latent membrane protein;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; ORF, open-
reading frame; PBS, phosphate-buffered saline; Pen Strep, penicillin–streptomycin;
RT-PCR, reverse transcription-polymerase chain reaction; TNBC, triple negative
breast cancer.
frequent HPV type worldwide, can convert non-invasive and
non-metastatic breast cancer cells into invasive and metastatic
ones (38). On the other hand, latent membrane protein 1 (LMP1)
is one of the major oncoproteins of EBV involved in inducing
cellular proliferation andmotility as well as restraining apoptosis,
thus indicating the role of EBV in carcinogenesis (39, 40). Several
recent investigations reported that high-risk HPV and EBV can
be co-present in different types of human carcinomas, including
cervical, head, and neck, colorectal in addition to the breast
(12, 14, 32, 36, 41–46). Moreover, it has been reported that the co-
presence of high-risk HPVs and EBV is associated with the tumor
grade and stage in addition to positive lymph nodes in breast
cancer and other types of human cancers (14, 32, 36, 44–46).
However, the outcome of oncoproteins cooperation of high-risk
HPVs and EBV in human cancer cells, including breast, has not
been explored yet. Therefore, we herein investigated for the first
time the cooperative effect of E6/E7 oncoproteins of HPV type 16
and LMP1 of EBV in two human breast cancer cell lines, MCF7
and MDA-MB-231, luminal A and triple negative breast cancer
(TNBC), respectively.
Our data point out that these oncoproteins can cooperate
to enhance cell proliferation and invasion of both cell lines in
comparison with their matched controls. Moreover, our study
revealed that this cooperation occurs via extracellular signal-
regulated kinases (Erk1/Erk2) and β-catenin signaling pathways.
MATERIALS AND METHODS
Cell Culture
Two different breast cancer cell lines (MCF7 and MDA-MB-
231) derived from females were purchased from American
Type Culture Collection (ATCC, Manassas VA, USA). Cell lines
were grown and expanded in the Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco R©, Life Technologies, Burlington, ON,
Canada) supplemented with 10% fetal bovine serum (FBS;
Invitrogen, Life Technologies, Burlington, ON, Canada), and
1% penicillin–streptomycin (Pen-Strep) antibiotic (Invitrogen,
Life Technologies). We used human normal mammary epithelial
(HNME) cells as control. HNME cells were maintained in
keratinocyte serum-free medium (KSFM) (1×) (Gibco R©, Life
Technologies) supplemented with 1% Pen-Strep antibiotic
(Invitrogen, Life Technologies). Cells were maintained at 37◦C
and in 5% CO2 atmosphere.
Transduction of Breast Cancer Cells With
E6/E7 and LMP1 of HPV-16 and EBV,
Respectively
Subconfluent breast cancer cell lines, MCF7 and MDA-MB-231,
as well as the control, HNME were transduced by retro-vectors
carrying E6/E7 in addition to LMP1, as previously illustrated
by our group (47–49). Briefly, HPV E6/E7 and EBV LMP1
open-reading frames (ORFs) were cloned into the murine-based
retroviral vector pLXSN (Takara Bio USA, Inc, Mountain View,
CA, USA). The constructs were transfected into a packaging
cell line PA317, and recombinant retrovirus was collected in the
supernatant. The resulting pLXSN virus was used to infect the
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early passage breast cancer and HNME cells. Cells were selected
with G418 at 300µg/ml and passaged in culture. Over 95%
of E6/E7 and LMP1 cancer cells were healthy after the G418
treatment. The transduced cells were subsequently maintained
in the long-term culture with the DMEM. The non-transduced
breast cancer cells (MCF7 and MDA-MB-231) and HNME cells
were used as control. On the one hand, we termed HNME cells
as HNME-Control, HNME-E6/E7, HNME-LMP1, and HNME-
E6/E7/LMP1. On the other hand, MCF7 cells were termed
as MCF7-Control, MCF7-E6/E7, MCF7-LMP1, and MCF7-
E6/E7/LMP1, while MDA-MB-231 cells were termed as MDA-
Control, MDA-E6/E7, MDA-LMP1, and MDA-E6/E7/LMP1.
As previously demonstrated by our group, normal control
cells and normal cells were transduced with pLXSN vector and
treated with G418 (38, 47, 50). We found that after the G418
treatment, ∼95% of the E6/E7-immortalized cells were healthy
(47). E6/E7 and/or LMP1 transduced cells were trypsinized and
passaged two times, when maintained on G418 (47). However,
the normal cells died after around 4 days of the G418 treatment;
pLXSN-transduced cells attained senescence after almost 10
passages (47).
For the transduction experiments, standard biosecurity and
institutional safety procedures were followed, and all procedures
were ethically approved by the Institutional Biosafety Committee
of Qatar University (QU-IBC-2018/22).
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl
Tetrazolium Bromide Cell Proliferation
Assay
The cell number was determined empirically after testing the
proliferative capacity of MCF7 and MDA-MB-231 cell lines in
comparison to the HNME cells in the 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays using an
increasing number of cells. On the one hand, 10,000 cells (MCF7
and MDA-MB-231) were plated onto a 96-well plate in DMEM
supplemented with 10% FBS and left to adhere for 24 h. On
the other hand, HNME cells (10,000 cells) were plated into a
96-well plate in KSFM and left to adhere for 24 h. To measure
proliferation in each well, 10 µl of an MTT stock solution (5
mg/ml) was added, and the plates were incubated for 4 h at
37◦C. This was followed by decanting the culture media from
the plates, dissolving the formazan crystals formed with 75 µl of
dimethyl sulfoxide (DMSO) with incubation for 5min, and then
measuring the absorbance at 560 nm using a plate reader.
Cell Cycle Analysis
MCF7, MDA-MB-231, and HNME cell lines were plated in
100mm dishes (1× 106 cells/dish) and were allowed to attach for
24 h. The cells were synchronized by culturing them overnight
in media with 10% FBS. Then, the cells were washed two times
with phosphate-buffered saline (PBS), and the culturing media
was replaced with fresh media enriched with 10% FBS. At 24 h,
cells were harvested by trypsinization, washed with PBS, and
fixed overnight in 70% ice-cold ethanol, and the DNAwas stained
with propidium iodide after RNAse treatment according to the
standard protocol (49). The cell cycle analysis was performed
using flow cytometry (BD Biosciences, San Jose, CA, USA), and
cells in G0/G1, S, G2/M, and the sub-G0/G1 (apoptotic) phases
were quantified.
Soft Agar Growth Assay
About 5,000 breast cancer cells (control and transduced) were
placed in DMEM containing 0.4% agar and plated over a layer
of DMEM containing 0.7% agar. Similarly, 2 × 103 HNME cells
(control and transduced) were placed in KSFM containing 0.4%
agar and plated over a layer of KSFM containing 0.7% agar. The
cultures were examined every 1–2 days for 3 weeks.
Cell Wounding Assay
Control cells (non-transfected) and transfected breast cancer
cell lines were seeded in six-well plates (5 × 105 cells/well)
and allowed to adhere for 24 h. The cells were kept in 2% FBS
overnight for synchronization. Following PBS wash, a sterile
pipette tip was used to scratch a vertical line in the middle in
each well. The detached cells were then removed by washing with
PBS. After washing with PBS, DMEM was added. Cell lines were
photographed after 24 h.
Invasion Assay
The cell invasion assay was carried out in 24-well Biocoat
Matrigel Invasion Chambers (pore size of 8µm, Corning, NY,
USA) as per the protocol of the manufacturer. In brief, the
bottom chamber was filled with DMEM supplemented with 10%
FBS, and the upper chamber was seeded with 5× 104 of different
cell lines in the media without FBS and then incubated at 37
◦
C.
After 24-h incubation, non-invasive cells were scraped with a
cotton swab, and cells that migrated to the lower surface of
the membrane were fixed with methanol and stained with 0.4%
crystal violet. For quantification, cells were counted under the
microscope in five predetermined fields as previously described
(49). The percentage of cell invasion was calculated with their
matched control. Each experiment was carried out in triplicates.
Preparation of RNA Samples and Reverse
Transcription-PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Valencia, CA, USA) from both control and transfected cells
(E6/E7, LMP1, and E6/E7+ LMP1) according to the instructions
of the manufacturer. For the reverse transcription (RT)-PCR
analysis, 100 ng of total RNA was reverse transcribed using
SuperScriptTM III One-Step RT-PCR System with PlatinumTM
Taq DNA Polymerase (Thermo Fisher Scientific, Waltham, MA,
USA). Samples were incubated in the Proflex Thermal Cycler
(Thermo Fisher Scientific, Waltham, MA, USA) for reverse
transcription at 60◦C for 30min, initial PCR activation step at
94◦C for 2min followed by 40 PCR cycles. Each cycle consisted
of annealing at 94◦C for 15 s, at 61◦C for 30 s, and at 68◦C for
1min. Final annealing was at 68◦C for 5min. The oligonucleotide
primers used in this study have been described previously (45,
51). The RT-PCR products were examined by electrophoresis on
1% agarose gel containing 0.2µg/ml ethidium bromide.
Frontiers in Oncology | www.frontiersin.org 3 March 2021 | Volume 11 | Article 630408
Gupta et al. HPV and EBV in Breast Cancer
Western Blot Analysis
Total cell lysates from the control and transduced breast cancer
cell lines were collected using the radioimmunoprecipitation
assay (RIPA) buffer (Santa Cruz Biotechnology, Inc., Dallas, TX,
USA). The lysate was incubated on ice for 30min and vortexed
briefly every 10min, and then centrifuged at 17,000 × g for
15min to collect the proteins. The final protein concentration in
the supernatant was determined using the BCA Assay Reagent
(Pierce Biotechnology, Waltham, MA, USA). Equal amounts (30
µg) of total cell extracts were boiled for 5min in an equal volume
of reducing buffer, resolved on 10% polyacrylamide gels, and
electroblotted onto nitrocellulose membranes. The membranes
were probed with a number of primary antibodies as follows:
anti-mouse E-cadherin (Abcam, Cambridge, UK: abID# ab1416),
anti-rabbit β-catenin (CST 9562), anti-rabbit phosphorylated
β-catenin (CST 4176), anti-rabbit Fascin (Abcam: abID#
ab183891), anti-rabbit Vimentin (Abcam: abID# 92547), anti-
rabbit anti-ERK1/ERK2 antibody (Abcam: abID# ab17942),
and anti-rabbit phosphorylated ERK1/ERK2 (Abcam: abID#
ab201015). Equal loading of the protein samples was assessed
by reprobing the membrane with anti-rabbit glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) antibody (Abcam: abID#
9485). Immunoreactivity was detected using chemiluminescence
as recommended by the manufacturer (Pierce Biotechnology,
Waltham, MA, USA).
In order to obtain a relative quantification of gene expressions,
images acquired from Western blotting were analyzed using
ImageJ software (National Institutes of Health, Bethesda, MD,
USA). The intensity of the bands relative to the GAPDH bands
was used to calculate a relative expression of proteins in each
cell line.
Statistical Analysis
Results were presented as mean ± SEM of triplicates from
three experiments, and the data were analyzed statistically
using one-way ANOVA and post-hoc test (multiple comparisons
using the Dunnett’s test) using the GraphPad Prism (Version
8.4.3, San Diego, CA, USA). Differences with p < 0.05 were
considered significant.
RESULTS
To assess the role of oncoviruses coinfection (high-risk HPVs
and EBV) in human breast cancer, we examined the cooperative
effects of E6/E7 of HPV type 16 and LMP1 of EBV on selected
parameters in two breast cancer cell lines, MCF7 and MDA-
MB-231. HNME cells were used as control. We transduced
MCF7, MDA-MB-231, and HNME cells with E6/E7 and LMP1,
individually and in combination, using a recombinant retroviral
system as described previously (38, 49). In our study, we utilized
polyclonal populations of MCF7-E6/E7, MCF-LMP1, MCF7-
E6/E7/LMP1, MDA-E6/E7, MDA-LMP1, MDA-E6/E7/LMP1,
andHNME (E6/E7, LMP1, and E6/E7/LMP1) cells; we confirmed
that these cell lines express E6/E7 and LMP1 in comparison with
their wild-type counterparts by RT-PCR (Figure 1).
We initially analyzed the proliferative ability of transduced cell
lines in comparison with their wild-type cells using the MTT
assay; our data revealed that E6/E7 and LMP1 alone enhance
cell proliferation in breast cancer cell lines, whereas the co-
presence of E6/E7 and LMP1 induces significant cell proliferation
(5-fold, 3.4-fold, and 2-fold) in both breast cancer and normal
mammary cells in comparison with cells expressing E6/E7 (2-
fold, 1.4-fold, and 1.3-fold) or LPM1 (3-fold, 1.8-fold, and 1-
fold) alone in MCF7, MDA-MB-231, and HNME, respectively,
and in control cells (Figure 2). Later, we analyzed cell cycle
progression of transduced cell lines in comparison with wild-
type cells using flow cytometric analysis. Our results showed
that E6/E7 and LMP1 oncoproteins together cause a significant
increase (1.1-fold, 1.2-fold, and 1.2-fold) in MCF7, MDA-MB-
231, and HNME, respectively (p= 0.04, p= 0.001, and p= 0.04)
in the percentage of G0 and G1 phase cells in comparison with
E6/E7 (1.0-fold, 1.1-fold, and 1.1-fold) or LMP1 (1-fold, 1.1-fold,
and 1.2-fold) alone and in control cells, indicating uncontrolled
cell growth (Figure 3).
Later, we assessed the colony formation of our cell lines using
soft agar assay, which is generally employed to confirm the
transformation ability of the cells; we noted a significant increase
in the number and size of colonies for both breast cancer cell
lines, MCF7 and MDA-MB-231, expressing E6/E7 and LMP1
together (3.8-fold and 7.6-fold) compared to E6/E7 (0.8-fold
and 1.2-fold) and LMP1 (1.4-fold and 3.2-fold) alone and their
matched controls in MCF7 and MDA-MB-231, respectively as
shown in Figures 4A,B. In contrast, HNME cell lines expressing
E6/E7 and LMP1 individually and together did not provoke
colony formation in soft agar (data not shown). Thus, it is clear
that E6/E7 and LMP1 can cooperate in HNME cells to stimulate
cell proliferation and deregulate cell cycle progression, but it does
not induce cellular transformation of HNME cells.
Based on the above data, we investigated cell motility and
invasiveness of transduced breast cancer cell lines and their wild-
type cells using wound-healing and invasion assays, respectively.
We found that the co-expression of E6/E7 and LMP1 enhances
significantly cell motility (0.7-fold and 6.3-fold) and invasive
abilities (0.4-fold for each cell line) of both the cell lines, MCF7
and MDA-MB-231, respectively, in comparison with E6/E7 and
LMP1 alone and with wild-type cells (Figures 5, 6).
Subsequently, we explored the expression patterns of
several important biomarkers of cell invasion and epithelial-
mesenchymal transition (EMT), including E-cadherin, β-catenin,
vimentin, and fascin genes in our cell line models. On the one
hand, our data showed that E6/E7/LMP1 cooperation reduces
the expression of E-cadherin and β-catenin in both breast cancer
cell lines, MCF7 and MDA-MB-231, in comparison with E6/E7
and LMP1 alone and control cells; on the other hand, vimentin
and fascin were significantly upregulated under the effect of
E6/E7/LMP1 cooperation as shown in Figure 7.
Vis-à-vis the underlying molecular mechanisms of
E6/E7/LMP1 cooperation, we assumed that β-catenin and
Erk1/Erk2 signaling pathways could be involved; this was based
on our recently published work on HPV and EBV interactions
in human cancer and EMT (42, 46, 52, 53). Our data pointed
out that E6/E7/LMP1 cooperation slightly deregulates the
expression patterns of β-catenin and Erk1/Erk2, whereas it
significantly induces the phosphorylation of both proteins in
comparison with E6/E7 and LPM1 alone and with wild-type
cells (Figure 7).
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FIGURE 1 | The RT-PCR analysis of E6/E7 and LMP1 expression of HPV and EBV, respectively, in MCF7-Control, MCF7-E6/E7, MCF-LMP1, MCF7-E6/E7/LMP1,
MDA-MB-231-Control, MDA-E6/E7, MDA-LMP1 and MDA-E6/E7/LMP1, HNME-Control, HNME-E6/E7, HNME-LMP1, and HNME-E6/E7/LMP1 cells. We note that
the cell lines express E6/E7 when transduced with E6/E7 alone and in combination, while LMP1 is present in cell lines transduced with LMP1 alone and in
combination. The controls did not express E6/E7 or LMP1.
FIGURE 2 | Effect of oncoproteins of HPV and EBV (E6/E7 and LMP1, respectively), on cell proliferation of breast cancer cell lines (A) MCF7 and (B) MDA-MB-231,
and (C) HNME after 24 h of using the MTT assay. Data are presented in comparison to controls, clearly cell lines that co-express E6/E7 and LMP1 exhibit the highest
proliferation rate (p < 0.001), whereas LMP1 and E6/E7 induce cell proliferation but to a lesser extent (p < 0.001). The data are expressed as a percent of growth ±
SEM.
DISCUSSION
In this study, we investigated for the first time, the cooperative
outcome of E6/E7 of HPV type 16 and LMP1 of EBV
oncoproteins in two human breast cancer cell lines, MCF7 and
MDA-MB-231, with regard to certain parameters related to
cell proliferation, cell cycle progression, and colony formation,
where HNME cells were used as control. Moreover, we
explored the cooperative role of E6/E7 and LMP1 in cell
motility and invasion as well as the expression patterns of
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FIGURE 3 | Cell cycle analysis of (A) MCF7 and (B) MDA-MB-231, and (C) HNME cells under the effect of E6/E7 and LMP1. Data demonstrate an increase in G0/G1
phase with a simultaneous reduction in S and G2/M phases of both cell lines.
FIGURE 4 | Effect of E6/E7/LMP1 on colony formation, in soft agar, in (A) MCF7 and (B) MDA-MB-231 cell lines. As shown, E6/E7/LMP1 induces colony formation of
MCF7 and MDA-MB-231 cells in comparison with their matched control cell lines; in contrast, E6/E7 and LMP1 are unable to incite HNME cells to form a colony in
soft agar (data not shown). Colonies were counted manually and expressed as mean ± SEM.
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FIGURE 5 | Outcome of E6/E7 and LMP1 of HPV16 and EBV, respectively, on cell motility in (A) MCF7 and (B) MDA-MB-231. We note that cotransduction of E6/E7
and LMP1 enhances cell motility of MCF7 and MDA-MB-231 cell lines in comparison with E6/E7 and LMP1 alone and with their wild-type counterparts.
FIGURE 6 | Effect of E6/E7 and LMP1 of HPV16 and EBV, respectively, on cell invasion in both breast cancer cell lines (A) MCF7 and (B) MDA-MB-231 cells.
E6/E7/LMP1 increases cell invasion ability of both cancer cell lines by ∼20% in comparison with their matched control cells (p < 0.05). The Boyden chambers were
used to assess the cell invasion ability of MCF7 and MDA-MB-231 cell lines.
EMT biomarkers, which are key regulators of cell invasion
and metastasis (54). Our data showed clearly that E6/E7 of
high-risk HPV type 16 can cooperate with LMP1 of EBV to
enhance cell proliferation and deregulate cell cycle progression
of MCF7, MDA-MB-231, and HNME cells; in addition, this
cooperation stimulates colony formation of human breast
cancer cells, but not in HNME cells, thus indicating its
inability to provoke neoplastic transformation of human normal
mammary cells.
Several studies reported that high-risk HPVs can be presented
in human breast cancer, especially types 16 and 18 that represent
the most frequent HPV types worldwide (10, 14, 18, 32); in this
context, it has been pointed out that HPV types 16 and 18 can
promote breast carcinogenesis (55, 56). On the one hand, and
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FIGURE 7 | Protein expression and molecular pathways of E6/E7 and LMP1 crosstalk in (A) MCF7 and (B) MDA-MB-231 cells. E6/E7/LMP1 downregulates
E-cadherin and β-catenin and upregulates vimentin and fascin in comparison with their control. Furthermore, E6/E7/LMP1 enhances the phosphorylation of β-catenin,
ERK1/2 while slightly increasing the total Erk1/2 expression. β-actin was used as a control in this assay.
similar to our present data, we have previously demonstrated
that E6/E7 of HPV type 16 converts non-invasive and non-
metastatic breast cancer cells into invasive and metastatic ones
(38). On the other hand, numerous recent reports, including
those from our laboratory, revealed that EBV can be detected
in human breast cancer where it can play a vital role in the
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initiation and/or progression of this cancer (12, 14, 36). More
recently, several investigations revealed that human oncoviruses,
especially high-risk HPVs and EBV can be co-present in different
types of human carcinomas, including cervical, head and neck,
colorectal, and the breast (12, 14, 32, 36, 41–46). In this context,
we have recently reported that high-risk HPVs and EBV are co-
present in 32 and 47% of breast cancer samples from Syrian
and Qatari women, respectively (14, 36); more significantly, our
studies pointed out that the co-presence of these oncoviruses is
associated with tumor grade and stage in addition to positive
lymph nodes in examined breast cancer samples from Syria and
Qatar (14, 36). However, the underlying molecular mechanisms
behind high-risk HPVs and EBV oncoproteins interaction
need to be identified. We herein explored the mechanism of
HPV/EBV oncoproteins cooperation in breast cancer cell line
models. It is worth noting that a previous study has shown a
significant association between the co-presence of HPVs and
EBV in luminal A and TNBC subtypes (36). Our present
data revealed that the HPV/EBV cooperation enhances colony
formation of luminal A and TNBC cancer cell lines, MCF7
and MDA-MB-231, respectively, which is a marker of cancer
aggressiveness; it stimulates cell proliferation and deregulates
cell cycle progression of these two breast cancer cell lines and
HNME cells.
On other hand, it is well-known today that in cancer
progression, EMT is a critical phenomenon characterized by
the disruption of intracellular tight junctions as well as the
loss of cell-cell contact (57). Moreover, in human carcinomas,
cancer progression is accompanied by loss of E-cadherin and
β-catenin in addition to enhanced expression of vimentin and
fascin, thereby promoting EMT (57–60). In this investigation, we
analyzed the effect of E6/E7 and LMP1 oncoproteins cooperation
on the expression patterns of E-cadherin, β-catenin, vimentin,
and fascin in luminal A and TNBC breast cancer cells (MCF7
and MDA-MB-231, respectively). We found that E6/E7/LMP1
downregulates the expression of E-cadherin and β-catenin, while
vimentin and fascin are upregulated, thus indicating loss of
cell–cell adhesion, especially E-cadherin/catenin complex. Our
data are in concordance with previous studies, where the loss
of E-cadherin expression is associated with EMT and promotes
cells to develop an invasive phenotype (61, 62). While, an
in vivo study in immune-deficient mice reported the loss of
E-cadherin to promote tumorigenicity, EMT, and metastasis
(63); another study by Kanai et al. (64) reported that loss of
E-cadherin correlates with increased invasiveness and poorly
differentiated breast carcinomas. On the other hand, in breast
cancer, increased expression of vimentin and mesenchymal
phenotypes correlates with more aggressive tumor characteristics
(65). Thus, we herein show for the first time that E6/E7 of
HPV type 16 cooperates with LMP1 of EBV to induce cell
motility and invasion of the two human breast cancer cell lines,
which is accompanied by the deregulation of EMT biomarkers.
Regarding the molecular pathways of this cooperation, we
assumed that β-catenin signaling pathways are involved in these
events since β-catenin can act as a transcription regulator as
well as a cell–cell adhesion molecule (66). Thus, it is plausible
that the presence of these oncoproteins and their cooperation
has an opposite effect on β-catenin pathways, particularly given
their role in inducing β-catenin phosphorylation and inhibiting
cell–cell adhesion leading to the enhancement of cell motility
and invasion of MCF7 and MDA-MB-231 cell lines. Thus,
our data indicate that the co-presence of these oncoviruses
stimulates mesenchymal transition (EMT), thus promoting
invasion and metastasis; concordantly, it is well-established that
metastatic breast cancer is significantly associated with poor
prognosis (67).
Moreover, our data revealed that the E6/E7/LMP1
oncoproteins cooperation enhances the phosphorylation of
β-catenin as well as Erk1/Erk2 pathway leading to loss of
E-cadherin expression and causing a cascade of cellular process
deregulations including proliferation, differentiation, motility,
and invasion (68). Earlier studies showed that Erk1/Erk2
activation enhances cell motility and invasion of several
types of human cancer cells, including breast (52–54, 69),
which is in accordance with our present data. However,
similar to our data, it has been shown that inactivation
of Erk1/2 pathways can affect cell proliferation and cause
G1 phase arrest (70, 71). Accordingly, in our cell line
models, the ERK activity provoked by the E6/E7/LMP1
cooperation caused an increase in G0/G1 phase of the
cell cycle.
CONCLUSIONS
In conclusion, our data point out for the first time that
oncoproteins of high-risk HPV and EBV cooperate to
stimulate cell proliferation and deregulate cell cycle
progression of human breast cancer and normal cells;
more significantly, this crosstalk can enhance cell motility
and invasion abilities of human breast cancer cells via β-
catenin and Erk1/Erk2 signaling pathways. Nevertheless,
future studies unraveling the mechanisms by which human
oncoviruses, including HPV and EBV, endure and stimulate
each other’s virulence is a major step toward developing
therapeutic strategies against human oncoviruses and their
associated cancers.
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